UroGen Pharma ( NASDAQ: URGN ) on Monday announced that it commenced an underwritten public offering to issue and sell its ordinary shares and pre-funded warrants. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. All the ordinary shares and pre-funded warrants to be sold in the proposed offering will be offered by UroGen.
URGN -3.34% after hours to $17.67 Source: Press Release More on UroGen Pharma UroGen: Q3 NDA Opens Hefty Revenue Opportunity UroGen Pharma Ltd.
(URGN) Q1 2024 Earnings Call Transcript UroGen surges on updated late-stage data for bladder cancer therapy Urogen files patent suit against Teva over cancer therapy Seeking Alpha’s Quant Rating on UroGen Pharma.
